RAD18

E3 ubiquitin-protein ligase RAD18 · Q9NS91 · RAD18 on Sugi Atlas →

0 patent compounds predicted against RAD18, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RAD18 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency PHASE2/PHASE3RECRUITING
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer PHASE1/PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) PHASE2RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects PHASE1/PHASE2COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) PHASE2COMPLETED
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma PHASE1/PHASE2RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors PHASE1/PHASE2RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS) PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation PHASE1RECRUITING
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Genetics of Prostate Cancer in Young Patients nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
Prognostic Biomarkers in Patients With Urothelial Carcinoma nanCOMPLETED
Endocrine Disruptors and Life STILe in Breast Cancer Development nanUNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RAD18 binder may also engage these)

ProteinNameSimilarity
Q9QXK2 0.997 Q9QXK2 →
O60934 0.986 O60934 →
Q9R207 0.986 Q9R207 →
P61594 0.985 P61594 →
Q7TT79 0.984 Q7TT79 →
P14629 0.984 P14629 →
ERCC5 DNA excision repair protein ERCC-5 0.984 landscape →
P61593 0.984 P61593 →
P61591 0.984 P61591 →
Q8NEM0 0.984 Q8NEM0 →
B2RYR0 0.983 B2RYR0 →
P61592 0.982 P61592 →
Q6P3Y5 0.982 Q6P3Y5 →
Q9JIL9 0.982 Q9JIL9 →
Q80XJ2 0.982 Q80XJ2 →
Q96T21 0.982 Q96T21 →
Q6GPJ8 0.982 Q6GPJ8 →
Q5IFK1 0.982 Q5IFK1 →
A0P8Z5 0.981 A0P8Z5 →
Q0IIM1 0.981 Q0IIM1 →
Q08DA3 0.981 Q08DA3 →
Q5RCV3 0.981 Q5RCV3 →
Q17RS7 0.980 Q17RS7 →
D2H3M0 0.980 D2H3M0 →
E2QTD3 0.980 E2QTD3 →
Q498E6 0.980 Q498E6 →
Q86YH2 0.980 Q86YH2 →
B2RX14 0.980 B2RX14 →
Q99MU0 0.979 Q99MU0 →
Q8BMI4 0.979 Q8BMI4 →